From tortuosity to GSV,
Varithena® can.

94% closure rate15 and favorable reimbursement

  • A single center retrospective review of 250 patients with C2-C6 CVI
  • Two patients experienced asymptomatic DVTs, one experienced a common femoral vein thrombus extension, and four experienced superficial venous thrombi, accompanied by minor discomfort.
 
tortousity
below the knee
recanallzation
all vein sizes
GSV

Varithena® is the can-do treatment your clinic needs.

Varithena® goes where thermal can’t and enhances results where thermal can16—all while offering a virtually pain-free experience with only 1.7% of patents reporting injection site pain in one published clinical trial8.

 
tortousity
below the knee
recanallzation
all vein sizes
GSV

Did you know Varithena® has two dedicated CPT codes?


 
 
tortousity
below the knee
recanallzation
all vein sizes
GSV
 

CASE STUDIES

Read Case Studies by your peers View More

EFFICACY

Learn about Varithena® pivotal trials View More

Reimbursement and Ordering

Learn about CPT codes 36465 & 36466 View More

INDICATIONS

Varithena®  (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins and visible varicosities of the great saphenous vein (GSV) system above and below the knee. Varithena®  improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.

IMPORTANT SAFETY INFORMATION

The use of Varithena®  is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease.

Severe allergic reactions have been reported following administration of liquid polidocanol, including anaphylactic reactions, some of them fatal. Observe patients for at least 10 minutes following injection and be prepared to treat anaphylaxis appropriately. Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Patients with underlying arterial disease may be at increased risk for tissue ischemia. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately.

Varithena®  can cause venous thrombosis. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing thrombosis. The most common adverse events observed were pain/discomfort in extremity, retained coagulum, injection site hematoma or pain, common femoral vein thrombus extension, superficial thrombophlebitis, and deep vein thrombosis.

Physicians administering Varithena®  must be experienced with venous procedures, possess a detailed working knowledge of the use of the duplex ultrasound in venous disease and be trained in the administration of Varithena® .

See Full Prescribing Information for Varithena®.

Follow Us